Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair–Related Genes

生殖系 生物 乳腺癌 内科学 细胞周期蛋白依赖激酶 癌症 癌症研究 转移性乳腺癌 支票2 肿瘤科 人口 种系突变 医学 基因 突变 遗传学 细胞周期 环境卫生
作者
Luisina Bruno,Alexis Ostinelli,Federico Waisberg,Diego Enrico,Carolina Ponce,Sergio Rivero,Albano Blanco,Martín Zarbá,Martín Loza,Verónica Fabiano,Mora Amat,María Teresa Pombo,Laura Noro,Matías Chacón,Federico Coló,Reinaldo Chacón,Jorge Nadal,Adrián Nervo,Victoria Costanzo
出处
期刊:JCO precision oncology [Lippincott Williams & Wilkins]
卷期号: (6) 被引量:28
标识
DOI:10.1200/po.21.00140
摘要

In recent years, unprecedented benefits have been observed with the development of cyclin-dependent kinase (CDK) 4 and 6 inhibitors for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. However, there is scarce evidence of their value in specific populations, such as patients carrying germline pathogenic variants in DNA repair-related genes.We retrospectively studied the efficacy of CDK 4/6 inhibitors plus endocrine therapy in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Three cohorts were compared, including patients harboring germline pathogenic variants in DNA repair-related genes (gBRCA1/2-ATM-CHEK2 mutated), those tested without these mutations (wild type [WT]), and the nontested subgroup. Relevant prognostic factors including age, metastatic site (visceral v nonvisceral), Eastern Cooperative Oncology Group, and prior treatment with CDK 4/6 inhibitors were stratified by univariate and multivariate Cox regression models.Among the total population (n = 217), 15 (6.9%) patients carried gBRCA1/2 (n = 10)-ATM (n = 4)-CHEK2 (n = 1) pathogenic variants, 45 (20.7%) were WT, and 157 (72.4%) were nontested. Gene pathogenic variant carriers were younger (P < .001). Most patients (164, 75.6%) had not received prior endocrine therapy in the advanced setting. Median progression-free survival was shorter in patients with evaluated germline pathogenic variants (10.2 months [95% CI, 5.7 to 14.7]), compared with WT and nontested patients (15.6 months [95% CI, 7.8 to 23.4], and (17.6 months [95% CI, 12.9 to 22.2]; P = .002). Consistently, a worse median overall survival was observed in the subgroup with germline pathogenic variants than in the WT group (P = .006). Multivariable analysis showed that mutation status was an independent prognostic factor of progression-free survival (P = .020) and overall survival (P = .012).In this retrospective real-world study, gBRCA1/2-ATM-CHEK2 pathogenic variants were independently associated with poor outcomes in patients with advanced breast cancer treated with CDK4/6 inhibitors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
温婉发布了新的文献求助20
1秒前
香香发布了新的文献求助10
1秒前
1秒前
waikeyan完成签到,获得积分10
1秒前
2秒前
管海彪完成签到,获得积分10
2秒前
3秒前
3秒前
3秒前
4秒前
4秒前
ckz完成签到,获得积分0
5秒前
天天快乐应助欢呼妙菱采纳,获得10
5秒前
5秒前
5秒前
MXiV完成签到,获得积分10
6秒前
pipashu应助青菜采纳,获得30
6秒前
魁梧的蜜蜂完成签到,获得积分10
6秒前
6秒前
咚咚糖发布了新的文献求助10
6秒前
7秒前
7秒前
磊磊完成签到,获得积分10
7秒前
jiayile发布了新的文献求助10
7秒前
迷你的面包完成签到,获得积分10
7秒前
luyong完成签到 ,获得积分10
8秒前
8秒前
Lucas应助分歧者咋咋采纳,获得10
8秒前
小陶子发布了新的文献求助10
8秒前
zyf完成签到,获得积分10
9秒前
今后应助最後まで采纳,获得10
9秒前
sdl发布了新的文献求助10
9秒前
少爷完成签到,获得积分10
9秒前
firy完成签到,获得积分10
9秒前
纯真新筠完成签到,获得积分10
9秒前
10秒前
zzzzz完成签到,获得积分10
10秒前
huoyan2006应助鹤鸣采纳,获得10
10秒前
西西完成签到,获得积分10
10秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969222
求助须知:如何正确求助?哪些是违规求助? 3514124
关于积分的说明 11171948
捐赠科研通 3249361
什么是DOI,文献DOI怎么找? 1794799
邀请新用户注册赠送积分活动 875431
科研通“疑难数据库(出版商)”最低求助积分说明 804779